GW Pharma (GWPH) Posts Q1 Loss of 9c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Tech stocks bolster Wall Street as Nvidia quells AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- First Financial to acquire Hickory Point Bank in $111.3M deal
Leerink Affirms GW Pharma (GWPH) at 'Outperform'; Focus Now on LGS Phase III Data
May 5, 2016 12:28 PM EDTLeerink affirms GW Pharma (Nasdaq: GWPH) at Outperform with a price target of $130 following Q1 results reported earlier.
Analyst Paul Matteis offered the following commentary: This morning GWPH reported F2Q16 EPS of £(0.06) versus our estimate of £(0.12) and specified timing of... More
